The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Tocilizumab treatment in COVID‐19: A single center experience
Open accessAbstract
Tocilizumab (TCZ), a monoclonal antibody against interleukin‐6 (IL‐6), emerged as an alternative treatment for COVID‐19 patients with a risk of cytokine storms recently. In the present study, we aimed to discuss the treatment response of TCZ therapy in COVID‐19 infected patients. The demographic, treatment, laboratory parameters of C‐reactive protein (CRP) and IL‐6 before and after TCZ therapy and clinical outcome in the 15 COVID‐19 patients were retrospectively assessed. Totally 15 patients with COVID‐19 were included in this study. Two of them were moderately ill, six were seriously ill and seven were critically ill. The TCZ was used in combination with methylprednisolone in eight patients. Five patients received the TCZ administration twice or more. Although TCZ treatment ameliorated the increased CRP in all patients rapidly, for the four critically ill patients who received an only single dose of TCZ, three of them (No. 1, 2, and 3) still dead and the CRP level in the rest one patient (No. 7) failed to return to normal range with a clinical outcome of disease aggravation. Serum IL‐6 level tended to further spiked firstly and then decreased after TCZ therapy in 10 patients. A persistent and dramatic increase of IL‐6 was observed in these four patients who failed treatment. TCZ appears to be an effective treatment option in COVID‐19 patients with a risk of cytokine storms. And for these critically ill patients with elevated IL‐6, the repeated dose of the TCZ is recommended.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30211-7 · Cited by 21,415
Self-citationPathological findings of COVID-19 associated with acute respiratory distress syndrome
Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., Liu, S., Zhao, P., Liu, H., Zhu, L., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30076-x · Cited by 8,545
Nishimoto, N., Terao, K., Mima, T., Nakahara, H., Takagi, N., & Kakehi, T. (2008) · Blood · doi:10.1182/blood-2008-05-155846 · Cited by 795
Xu, Y.-H., Dong, J.-H., An, W.-M., Lv, X.-Y., Yin, X.-P., Zhang, J.-Z., Dong, L., Ma, X., Zhang, H.-J., & Gao, B.-L. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.02.017 · Cited by 506
A panoramic review of IL-6: Structure, pathophysiological roles and inhibitors
Kaur, S., Bansal, Y., Kumar, R., & Bansal, G. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115327 · Cited by 449
Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome
Kotch, C., Barrett, D., & Teachey, D. T. (2019) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2019.1629904 · Cited by 324
IL-1βand IL-6 Upregulation in Children with H1N1 Influenza Virus Infection
Chiaretti, A., Pulitanò, S., Barone, G., Ferrara, P., Romano, V., Capozzi, D., & Riccardi, R. (2013) · Mediators of Inflammation · doi:10.1155/2013/495848 · Cited by 77
Cited by
IL-6 in inflammation, autoimmunity and cancer
Hirano, T. (2021) · International Immunology · doi:10.1093/intimm/dxaa078 · Cited by 1,453
Gianfrancesco, M., Hyrich, K. L., Al-Adely, S., Carmona, L., Danila, M. I., Gossec, L., Izadi, Z., Jacobsohn, L., Katz, P., Lawson-Tovey, S., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217871 · Cited by 1,141
Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia
Rosas, I. O., Bräu, N., Waters, M., Go, R. C., Hunter, B. D., Bhagani, S., Skiest, D., Aziz, M. S., Cooper, N., Douglas, I. S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028700 · Cited by 1,125
SARS-CoV-2 infection: The role of cytokines in COVID-19 disease
Costela-Ruiz, V. J., Illescas-Montes, R., Puerta-Puerta, J. M., Ruiz, C., & Melguizo-Rodríguez, L. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.06.001 · Cited by 1,121
Naqvi, A. A. T., Fatima, K., Mohammad, T., Fatima, U., Singh, I. K., Singh, A., Atif, S. M., Hariprasad, G., Hasan, G. M., & Hassan, M. I. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165878 · Cited by 1,114
Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies
Tang, Y., Liu, J., Zhang, D., Xu, Z., Ji, J., & Wen, C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01708 · Cited by 1,094
Bourgonje, A. R., Abdulle, A. E., Timens, W., Hillebrands, J., Navis, G. J., Gordijn, S. J., Bolling, M. C., Dijkstra, G., Voors, A. A., Osterhaus, A. D., et al. (2020) · The Journal of Pathology · doi:10.1002/path.5471 · Cited by 1,081
Tocilizumab in patients with severe COVID-19: a retrospective cohort study
Guaraldi, G., Meschiari, M., Cozzi-Lepri, A., Milic, J., Tonelli, R., Menozzi, M., Franceschini, E., Cuomo, G., Orlando, G., Borghi, V., et al. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30173-9 · Cited by 939
T cell responses in patients with COVID-19
Chen, Z., & John Wherry, E. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0402-6 · Cited by 797
Wang, J., Jiang, M., Chen, X., & Montaner, L. J. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.3covr0520-272r · Cited by 741
How COVID-19 induces cytokine storm with high mortality
Hojyo, S., Uchida, M., Tanaka, K., Hasebe, R., Tanaka, Y., Murakami, M., & Hirano, T. (2020) · Inflammation and Regeneration · doi:10.1186/s41232-020-00146-3 · Cited by 663
Jamilloux, Y., Henry, T., Belot, A., Viel, S., Fauter, M., El Jammal, T., Walzer, T., François, B., & Sève, P. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102567 · Cited by 658
Elevated interleukin‐6 and severe COVID‐19: A meta‐analysis
Aziz, M., Fatima, R., & Assaly, R. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25948 · Cited by 554
Immunopathology of Hyperinflammation in COVID-19
Gustine, J. N., & Jones, D. (2021) · The American Journal of Pathology · doi:10.1016/j.ajpath.2020.08.009 · Cited by 516
Henderson, L. A., Canna, S. W., Friedman, K. G., Gorelik, M., Lapidus, S. K., Bassiri, H., Behrens, E. M., Ferris, A., Kernan, K. F., Schulert, G. S., et al. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41454 · Cited by 531
The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection
Pons, S., Fodil, S., Azoulay, E., & Zafrani, L. (2020) · Critical Care · doi:10.1186/s13054-020-03062-7 · Cited by 517
Tocilizumab for Treatment of Mechanically Ventilated Patients With COVID-19
Somers, E. C., Eschenauer, G. A., Troost, J. P., Golob, J. L., Gandhi, T. N., Wang, L., Zhou, N., Petty, L. A., Baang, J. H., Dillman, N. O., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa954 · Cited by 497
Drug repurposing approach to fight COVID-19
Singh, T. U., Parida, S., Lingaraju, M. C., Kesavan, M., Kumar, D., & Singh, R. K. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00155-6 · Cited by 480
Severe covid-19 pneumonia: pathogenesis and clinical management
Attaway, A. H., Scheraga, R. G., Bhimraj, A., Biehl, M., & Hatipoğlu, U. (2021) · BMJ · doi:10.1136/bmj.n436 · Cited by 437
Henderson, L. A., Canna, S. W., Friedman, K. G., Gorelik, M., Lapidus, S. K., Bassiri, H., Behrens, E. M., Ferris, A., Kernan, K. F., Schulert, G. S., et al. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41616 · Cited by 412
Campochiaro, C., Della-Torre, E., Cavalli, G., De Luca, G., Ripa, M., Boffini, N., Tomelleri, A., Baldissera, E., Rovere-Querini, P., Ruggeri, A., et al. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.05.021 · Cited by 394
Inhibition of Bruton tyrosine kinase in patients with severe COVID-19
Roschewski, M., Lionakis, M. S., Sharman, J. P., Roswarski, J., Goy, A., Monticelli, M. A., Roshon, M., Wrzesinski, S. H., Desai, J. V., Zarakas, M. A., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abd0110 · Cited by 357
An immune-based biomarker signature is associated with mortality in COVID-19 patients
Abers, M. S., Delmonte, O. M., Ricotta, E. E., Fintzi, J., Fink, D. L., de Jesus, A. A. A., Zarember, K. A., Alehashemi, S., Oikonomou, V., Desai, J. V., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.144455 · Cited by 340
Autoinflammatory and autoimmune conditions at the crossroad of COVID-19
Rodríguez, Y., Novelli, L., Rojas, M., De Santis, M., Acosta-Ampudia, Y., Monsalve, D. M., Ramírez-Santana, C., Costanzo, A., Ridgway, W. M., Ansari, A. A., et al. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102506 · Cited by 312
Davoudi-Monfared, E., Rahmani, H., Khalili, H., Hajiabdolbaghi, M., Salehi, M., Abbasian, L., Kazemzadeh, H., & Yekaninejad, M. S. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01061-20 · Cited by 306
Potential intestinal infection and faecal–oral transmission of SARS-CoV-2
Guo, M., Tao, W., Flavell, R. A., & Zhu, S. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00416-6 · Cited by 304
Pharmaco-Immunomodulatory Therapy in COVID-19
Rizk, J. G., Kalantar-Zadeh, K., Mehra, M. R., Lavie, C. J., Rizk, Y., & Forthal, D. N. (2020) · Drugs · doi:10.1007/s40265-020-01367-z · Cited by 288
Zhang, J. J. Y., Lee, K. S., Ang, L. W., Leo, Y. S., & Young, B. E. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa576 · Cited by 285
Shi, L., Huang, H., Lu, X., Yan, X., Jiang, X., Xu, R., Wang, S., Zhang, C., Yuan, X., Xu, Z., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00488-5 · Cited by 283
Biran, N., Ip, A., Ahn, J., Go, R. C., Wang, S., Mathura, S., Sinclaire, B. A., Bednarz, U., Marafelias, M., Hansen, E., et al. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30277-0 · Cited by 275
D'Silva, K. M., Serling-Boyd, N., Wallwork, R., Hsu, T., Fu, X., Gravallese, E. M., Choi, H. K., Sparks, J. A., & Wallace, Z. S. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217888 · Cited by 267
Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients
Klopfenstein, T., Zayet, S., Lohse, A., Balblanc, J.-C., Badie, J., Royer, P.-Y., Toko, L., Mezher, C., Kadiane-Oussou, N. J., Bossert, M., et al. (2020) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2020.05.001 · Cited by 266
Estradiol, Progesterone, Immunomodulation, and COVID-19 Outcomes
Mauvais-Jarvis, F., Klein, S. L., & Levin, E. R. (2020) · Endocrinology · doi:10.1210/endocr/bqaa127 · Cited by 266
Tocilizumab for the treatment of severe coronavirus disease 2019
Alattar, R., Ibrahim, T. B. H., Shaar, S. H., Abdalla, S., Shukri, K., Daghfal, J. N., Khatib, M. Y., Aboukamar, M., Abukhattab, M., Alsoub, H. A., et al. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25964 · Cited by 259
Systematic Review of COVID-19 Related Myocarditis: Insights on Management and Outcome
Sawalha, K., Abozenah, M., Kadado, A. J., Battisha, A., Al-Akchar, M., Salerno, C., Hernandez-Montfort, J., & Islam, A. M. (2021) · Cardiovascular Revascularization Medicine · doi:10.1016/j.carrev.2020.08.028 · Cited by 217
Wang, Y., Zheng, J., Islam, M. S., Yang, Y., Hu, Y., & Chen, X. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59534 · Cited by 71
Metadata
- Authors
- Luo, P., Liu, Y., Qiu, L., Liu, X., Liu, D., & Li, J.
- Venue
- Journal of Medical Virology
- Publisher
- Wiley
- Published
- 2020-04-15
- Volume
- 92
- Issue
- 7
- Pages
- 814-818
- ISSN
- 0146-6615 (ISSN-L)
- 1096-9071
- OpenAlex
- W3014333693
- Cited by
- 1,237
- References
- 8
- FWCI
- 35.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.